A Page1, S O'Rourke2, M Brennan3, L Clooney4, D Le Blanc5, J Griffin6, M Eogan7, R J Drew8,9,10. 1. Trinity College, University of Dublin, Dublin 2, Ireland. 2. Department of Microbiology, Temple St Children's University Hospital, Dublin 7, Ireland. 3. Department of Midwifery, Rotunda Hospital, Dublin 1, Ireland. 4. Pharmacy Department, Rotunda Hospital, Dublin 1, Ireland. 5. Department of Microbiology, Rotunda Hospital, Dublin 1, Ireland. 6. Department of Research, Rotunda Hospital, Dublin 1, Ireland. 7. Department of Obstetrics, Rotunda Hospital, Dublin 1, Ireland. 8. Department of Microbiology, Temple St Children's University Hospital, Dublin 7, Ireland. rdrew@rotunda.ie. 9. Department of Microbiology, Rotunda Hospital, Dublin 1, Ireland. rdrew@rotunda.ie. 10. Department of Microbiology, Royal College of Surgeons in Ireland, Dublin 2, Ireland. rdrew@rotunda.ie.
Abstract
BACKGROUND: The Xpert MRSA/SA blood culture assay (Cepheid, USA) is a rapid PCR test which can be used for positive blood cultures where Gram-positive cocci in clusters are seen. It can detect Staphylococcus aureus and also the mecA gene, which encodes for β-lactam resistance. The assay was introduced into the Rotunda Hospital for positive blood cultures to allow earlier detection of MRSA and methicillin susceptible S. aureus. AIM: To assess the impact of the Xpert MRSA/SA blood culture assay on the management of obstetric patients with a positive blood culture where Gram-positive cocci in clusters were seen. The main outcome measures were duration of intravenous antimicrobials and length of admission. METHODS: Pre-intervention and post-intervention groups were identified relating to whether or not the test was in use at the time. A standardised form was used to retrospectively review the medical notes and laboratory results. RESULTS: There were 35 obstetric patients with positive blood cultures with Gram-positive cocci in clusters in the pre-intervention group and 22 cases in the post-intervention group. All 22 positive blood cultures in the post-intervention period were correctly identified. The antimicrobial duration was reduced from a median of 55.5-43.5 h and length of admission reduced from a median of 66.5-56 h (Mann-Whitney U value = 161, p = 0.46 and U value = 256, p = 0.15, respectively). CONCLUSION: This study has shown a reduction in the median duration of intravenous antimicrobials and admission; however, larger multi-centre studies are needed to evaluate this potential benefit further.
BACKGROUND: The Xpert MRSA/SA blood culture assay (Cepheid, USA) is a rapid PCR test which can be used for positive blood cultures where Gram-positive cocci in clusters are seen. It can detect Staphylococcus aureus and also the mecA gene, which encodes for β-lactam resistance. The assay was introduced into the Rotunda Hospital for positive blood cultures to allow earlier detection of MRSA and methicillin susceptible S. aureus. AIM: To assess the impact of the Xpert MRSA/SA blood culture assay on the management of obstetricpatients with a positive blood culture where Gram-positive cocci in clusters were seen. The main outcome measures were duration of intravenous antimicrobials and length of admission. METHODS: Pre-intervention and post-intervention groups were identified relating to whether or not the test was in use at the time. A standardised form was used to retrospectively review the medical notes and laboratory results. RESULTS: There were 35 obstetricpatients with positive blood cultures with Gram-positive cocci in clusters in the pre-intervention group and 22 cases in the post-intervention group. All 22 positive blood cultures in the post-intervention period were correctly identified. The antimicrobial duration was reduced from a median of 55.5-43.5 h and length of admission reduced from a median of 66.5-56 h (Mann-Whitney U value = 161, p = 0.46 and U value = 256, p = 0.15, respectively). CONCLUSION: This study has shown a reduction in the median duration of intravenous antimicrobials and admission; however, larger multi-centre studies are needed to evaluate this potential benefit further.
Authors: Abigail M Frye; Catherine A Baker; D Leif Rustvold; Kim A Heath; Jessica Hunt; James E Leggett; Margret Oethinger Journal: J Clin Microbiol Date: 2011-11-09 Impact factor: 5.948
Authors: Cassandra D Kelly-Cirino; Patricia S Curry; Jamie L Marola; Niels K Helstrom; Max Salfinger Journal: Diagn Microbiol Infect Dis Date: 2016-08-16 Impact factor: 2.803
Authors: Y M Alahmadi; M A Aldeyab; J C McElnay; M G Scott; F W Darwish Elhajji; F A Magee; M Dowds; C Edwards; L Fullerton; A Tate; M P Kearney Journal: J Hosp Infect Date: 2011-01-07 Impact factor: 3.926
Authors: Blake W Buchan; Stephen Allen; Carey-Ann D Burnham; Erin McElvania TeKippe; Thomas Davis; Michael Levi; Donna Mayne; Preeti Pancholi; Ryan F Relich; Richard Thomson; Nathan A Ledeboer Journal: J Clin Microbiol Date: 2014-12-24 Impact factor: 5.948
Authors: Yuliya Zboromyrska; Cristina De la Calle; Marcelo Soto; Laura Sampietro-Colom; Alex Soriano; Míriam José Alvarez-Martínez; Manel Almela; Francesc Marco; Ruth Arjona; Nazaret Cobos-Trigueros; Laura Morata; José Mensa; José Antonio Martínez; Aurea Mira; Jordi Vila Journal: PLoS One Date: 2016-08-29 Impact factor: 3.240
Authors: Natalia Kolesnik-Goldmann; Elias Bodendoerfer; Kim Röthlin; Sebastian Herren; Frank Imkamp; Martina Marchesi; Stefano Mancini Journal: Microbiol Spectr Date: 2021-07-28